

# Development of first-in-class small molecule inhibitor targeting novel transcriptional regulator for cancer immunotherapy

SAMJIN PHARM.CO.,LTD.

<b>Disease Area</b>	<b><i>Oncology</i></b>
<b>Product Type</b>	Small molecules
<b>Indication</b>	ICI-resistant solid tumor(melanoma, colon cancer and ovarian cancer)
<b>Target</b>	Novel transcriptional regulator function in both cancer and immune cells
<b>Mechanism of Action</b>	By simultaneously targeting T cells and cancer cells, SJN309 increases T cell activity and pro-inflammatory cytokines and inhibits cancer growth and immune evasion.
<b>Competitiveness</b>	A first-in-class small molecule inhibitor targeting novel transcriptional regulator for ICI-resistant cancer treatment
<b>Development Stage</b>	<b><i>Hit to Lead</i></b>
<b>Route of Administration</b>	PO
<b>Key Data</b>	The synergistic anti-cancer effect of SJN309 in combination with ICIs was proven in mouse syngeneic melanoma model(TGI 70%). In addition, SJN309 exhibited excellent ADME and PK profiles.
<b>IP</b>	Domestic application in progress